Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size
| العنوان: | Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size |
|---|---|
| المؤلفون: | Landh, E, M Moir, L, Bradbury, P, Traini, D, M Young, P, Ong, HX |
| بيانات النشر: | FUTURE MEDICINE LTD, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology, Nanoscience & Nanotechnology |
| الوصف: | Background: Lymphangioleiomyomatosis (LAM) is characterized by growth of smooth muscle-like cells in the lungs that spread to other organs via lymphatic vessels. Current oral rapamycin treatment is limited by low bioavailability of approximately 15%. Aim: The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics. Method: Three Rapa-SLN formulations (200-1000 nm) were produced and assessed for particle characteristics and further for toxicity and performance in vitro. Results: Rapa-SLNs of 200 nm inhibited proliferation in TSC2-negative mouse embryonic fibroblast cells and penetrated the respiratory epithelium and lymphatic endothelium significantly faster compared with free rapamycin and larger Rapa-SLNs. Conclusion: Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients. |
| وصف الملف: | Print-Electronic; application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=od_______363::c76b15bff0407cda76bc4047bc44ac1a https://hdl.handle.net/10453/149370 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.od.......363..c76b15bff0407cda76bc4047bc44ac1a |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.od.......363..c76b15bff0407cda76bc4047bc44ac1a 845 3 unknown 844.712036132813 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od.......363..c76b15bff0407cda76bc4047bc44ac1a&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=od_______363::c76b15bff0407cda76bc4047bc44ac1a# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Landh%2C+E%22">Landh, E</searchLink><br /><searchLink fieldCode="AR" term="%22M+Moir%2C+L%22">M Moir, L</searchLink><br /><searchLink fieldCode="AR" term="%22Bradbury%2C+P%22">Bradbury, P</searchLink><br /><searchLink fieldCode="AR" term="%22Traini%2C+D%22">Traini, D</searchLink><br /><searchLink fieldCode="AR" term="%22M+Young%2C+P%22">M Young, P</searchLink><br /><searchLink fieldCode="AR" term="%22Ong%2C+HX%22">Ong, HX</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => FUTURE MEDICINE LTD, 2020. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%220306+Physical+Chemistry+%28incl%2E+Structural%29%2C+1004+Medical+Biotechnology%2C+1007+Nanotechnology%22">0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology</searchLink><br /><searchLink fieldCode="DE" term="%22Nanoscience+%26+Nanotechnology%22">Nanoscience & Nanotechnology</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: Lymphangioleiomyomatosis (LAM) is characterized by growth of smooth muscle-like cells in the lungs that spread to other organs via lymphatic vessels. Current oral rapamycin treatment is limited by low bioavailability of approximately 15%. Aim: The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics. Method: Three Rapa-SLN formulations (200-1000 nm) were produced and assessed for particle characteristics and further for toxicity and performance in vitro. Results: Rapa-SLNs of 200 nm inhibited proliferation in TSC2-negative mouse embryonic fibroblast cells and penetrated the respiratory epithelium and lymphatic endothelium significantly faster compared with free rapamycin and larger Rapa-SLNs. Conclusion: Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients. ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => Print-Electronic; application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=od_______363::c76b15bff0407cda76bc4047bc44ac1a" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=od_______363::c76b15bff0407cda76bc4047bc44ac1a</link><br /><link linkTarget="URL" linkTerm="https://hdl.handle.net/10453/149370" linkWindow="_blank">https://hdl.handle.net/10453/149370</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.od.......363..c76b15bff0407cda76bc4047bc44ac1a ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => 0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
[Type] => general
)
[1] => Array
(
[SubjectFull] => Nanoscience & Nanotechnology
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Landh, E
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => M Moir, L
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bradbury, P
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Traini, D
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => M Young, P
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ong, HX
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 21
[M] => 08
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
)
)
)
)
)
|
| IllustrationInfo |